CD274 and non-small cell lung carcinoma: The first PD-(L)1 inhibitor monotherapy receiving the European Medicine Agency’s approval as a first-line treatment for advanced NSCLC was pembrolizumab and approved in April 2017 and the first PD-(L)1 inhibitor-based combination regimen was approved in July 2018 (pembrolizumab in combination with pemetrexed and platinum chemotherapy), followed by other PD-(L)1-based regimens from 2019 to 2021.